1,064 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
JNJ Johnson & Johnson $139.96 $375.48B N/A
Article Searches
Dow 30 Stock Roundup: Apple Launches New Services, JPMorgan to Trim Wealth Jobs http://www.zacks.com/stock/news/366674/dow-30-stock-roundup-apple-launches-new-services-jpmorgan-to-trim-wealth-jobs?cid=CS-ZC-FT-366674 Mar 29, 2019 - The index enjoyed quite a positive week even as a yield curve inversion weighed on broader markets.
AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes http://www.zacks.com/stock/news/366338/astrazenecas-forxiga-gets-nod-in-japan-for-type-i-diabetes?cid=CS-ZC-FT-366338 Mar 28, 2019 - AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.
J&J Files sBLA for Darzalex in Expanded Myeloma Patient Group http://www.zacks.com/stock/news/365606/jj-files-sbla-for-darzalex-in-expanded-myeloma-patient-group?cid=CS-ZC-FT-365606 Mar 27, 2019 - J&J (JNJ) submits sBLA seeking approval for Darzalex combination regimen in newly-diagnosed, transplant eligible multiple myeloma patient population
Bayer & JNJ Settle Numerous Xarelto Lawsuits for $775 Million http://www.zacks.com/stock/news/364998/bayer-jnj-settle-numerous-xarelto-lawsuits-for-%24775-million?cid=CS-ZC-FT-364998 Mar 26, 2019 - Bayer (BAYRY) and partner Johnson & Johnson settle about 25,000 claims over blood thinner, Xarelto for $775 million.
J&J Files Application for Darzalex Label Expansion in Europe http://www.zacks.com/stock/news/364217/jj-files-application-for-darzalex-label-expansion-in-europe?cid=CS-ZC-FT-364217 Mar 25, 2019 - J&J (JNJ) seeks an approval for Darzalex combo pertaining to the newly diagnosed, transplant-ineligible multiple myeloma patient population in the EU.
Biogen’s Big Bet in Alzheimer’s Disease Is a Bust https://www.fool.com/investing/2019/03/21/biogens-big-bet-in-alzheimers-disease-is-a-bust.aspx?source=iedfolrf0000001 Mar 21, 2019 - The big biotech's pivot from multiple sclerosis to Alzheimer's disease was dealt a decisive blow today.
Alkermes Focuses on Pipeline, Depends on Partners for Funds http://www.zacks.com/stock/news/362777/alkermes-focuses-on-pipeline-depends-on-partners-for-funds?cid=CS-ZC-FT-362777 Mar 21, 2019 - Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.
3 Dividend Stocks Ideal for Retirees https://www.fool.com/investing/2019/03/19/3-dividend-stocks-ideal-for-retirees.aspx?source=iedfolrf0000001 Mar 19, 2019 - These two popular dividend stocks, and one you've probably never heard of, should fit a retiree's portfolio.
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others http://www.zacks.com/stock/news/359854/pharma-stock-roundup-regulatory-updates-from-mrk-pfe-jj-agn-others?cid=CS-ZC-FT-359854 Mar 15, 2019 - Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
J&J Seeks Approval for Darzalex in Expanded Patient Group http://www.zacks.com/stock/news/359663/jj-seeks-approval-for-darzalex-in-expanded-patient-group?cid=CS-ZC-FT-359663 Mar 15, 2019 - J&J (JNJ) files sBLA seeking approval for Darzalex combination regimen in newly- diagnosed, transplant ineligible multiple myeloma patient population.

Pages: 1234567891011...107

<<<Page 6>